DIRECT-TO-CONSUMER ADVERTISING

CNA POSITION

Consumers have the right to evidence-based, independently developed, comparative information on which to make decisions about their health. The Canadian Nurses Association (CNA) believes that in developing and distributing information, public safety must be paramount. CNA recognizes that, with regard to over-the-counter drugs and prescription products, information distribution is one of the influencers of use and prescribing patterns. At the same time, CNA recognizes that expertise and skill are needed to diagnose health problems and select appropriate remedies.

CNA believes, therefore, that the federal government must maintain and enforce the legislated prohibition on distributing information to consumers about:

• pharmacological treatment options for diseases and conditions;
• new products offering unspecified treatment options; and
• product-specific therapeutic claims.

CNA is prepared to work with governments and others to establish an independent process to assess and approve the content of non-promotional information proposed for dissemination to consumers about over-the-counter drugs and prescription products.

CNA also believes that governments must invest in research to assess the impact of information disseminated to consumers about over-the-counter drugs and prescription products on health outcomes and health care. This research should build on:

• existing studies of the effects of such information;
• consumption and overall costs of over-the-counter drugs and prescription products;
• interactions (qualitative and quantitative) between consumers and their health professional(s); and
• the prescribing practices of health professionals.

In addition, CNA recommends that governments and producers of over-the-counter drugs and prescription products develop and implement programs to promote patient safety by improving consumer understanding about products and their impact.

BACKGROUND

Information about over-the-counter drugs and prescription products appears in magazines, direct-mail solicitation, radio, television, billboards and on the Internet. Except in the United States and New Zealand, such advertising is prohibited. The European community recently reconfirmed its prohibition against advertising of these products.
In Canada, the legislative framework for the prohibition of direct-to-consumer advertising (DTCA) is provided by the Food and Drugs Act. Federal government policy has defined three types of advertising related to over-the-counter drugs and prescription products. These are:

- consumer information about diseases, conditions and new, unspecified treatment options;
- product name information; and
- product-specific information related to specific therapeutic claims.

Between 1997 and 2001, spending in the United States on information dissemination to consumers about over-the-counter drugs and prescription products doubled to $2.7 billion, according to an October 2002 report by the U.S. General Accounting Office. In the next two years, that number is expected to rise to $5 billion. The report claimed that drugs promoted directly to consumers are among the best-selling medications. The report also noted that sales of prescription drugs promoted to consumers have increased faster than sales of drugs not advertised.

In the January 2003 Journal of the American Medical Association, Mello et al. point to research that suggests drug advertising, which combines promotional and risk-related information, may confuse consumers regarding the safety and effectiveness of products. Moreover, the article argues that risk information is poorly conveyed in advertisements, citing time and space constraints that require consumers to rely on other media to obtain comprehensive information.

Approved by the CNA Board of Directors, October 2004

**Bibliography**

The author consulted the following texts in the creation of this document.


